SARS-CoV-2 Vaccines and Adverse Effects in Gynecology and Obstetrics: The First Italian Retrospective Study.
Miriam DellinoBruno LamannaMarina VinciguerraStefano TermitePasquale StefanizziAntonio MalvasiGiovanni Di VagnoGennaro CormioVera LoizziGerardo CazzatoRaffaele TinelliEttore CicinelliVincenzo PintoAntonella DanieleEugenio MaioranoLeonardo RestaDanila de VitoSalvatore ScaccoEleonora NacchieroPublished in: International journal of environmental research and public health (2022)
The most common effects reported by the Italian Medicine Agency following administration of SARS-CoV-2 vaccine are myalgia, soreness to the arm of inoculation, fever, and asthenia. To date, there are no specific and official reports registered by the Italian Medicine Agency on possible alterations of the menstrual cycle, or of the female reproductive system, following the vaccine. Actually, clinical experience showed a spread of transient adverse drug reactions of the menstrual cycle, following the administration of all COVID-19 vaccine types, both mRNA and Adenovirus vectored ones. In this work, we conducted the first retrospective study on Italian patients vaccinated for SARS-CoV-2 in the period between April 2021 and April 2022, to report the onset of menstrual changes after the vaccine in order to understand: etiology, duration of possible adverse effects, and the extent of the phenomenon. We recruited 100 women aged 18-45, vaccinated for SARS-CoV-2, who were asked to complete a questionnaire consisting of 12 multiple choice questions about the effects of the vaccine on the reproductive system. Thirty-seven of them received three doses of the vaccine, while the remaining 63 received two doses. Symptoms such as delayed menstruation and abnormal uterine bleeding (metrorrhagia, menometrorrhagia, and menorrhagia) were generally reported within the first three weeks of vaccination, especially after the second dose, with a percentage of 23% and 77%, respectively. These preliminary data suggest that this problem may be broader and deserving of further investigation in the future.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- adverse drug
- end stage renal disease
- electronic health record
- ejection fraction
- coronavirus disease
- type diabetes
- chronic kidney disease
- physical activity
- metabolic syndrome
- skeletal muscle
- big data
- pregnancy outcomes
- pregnant women
- prognostic factors
- adipose tissue
- patient reported outcomes
- binding protein
- data analysis
- drug administration
- breast cancer risk